Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Iovance Biotherapeutics (IOVA) Net Margin: 2011-2025

Historic Net Margin for Iovance Biotherapeutics (IOVA) over the last 4 years, with Sep 2025 value amounting to -135.28%.

  • Iovance Biotherapeutics' Net Margin rose 739.00% to -135.28% in Q3 2025 from the same period last year, while for Sep 2025 it was -158.79%, marking a year-over-year increase of 29239.00%. This contributed to the annual value of -226.84% for FY2024, which is 3711681.00% up from last year.
  • Iovance Biotherapeutics' Net Margin amounted to -135.28% in Q3 2025, which was up 27.37% from -186.27% recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' Net Margin ranged from a high of -106.62% in Q4 2024 and a low of -44,750.00% during Q2 2023.
  • In the last 3 years, Iovance Biotherapeutics' Net Margin had a median value of -273.77% in 2025 and averaged -11,006.57%.
  • Data for Iovance Biotherapeutics' Net Margin shows a peak YoY surged of 4,443,797bps (in 2024) over the last 5 years.
  • Over the past 3 years, Iovance Biotherapeutics' Net Margin (Quarterly) stood at -24,140.66% in 2023, then soared by 2,403,404bps to -106.62% in 2024, then skyrocketed by 739bps to -135.28% in 2025.
  • Its Net Margin stands at -135.28% for Q3 2025, versus -186.27% for Q2 2025 and -235.51% for Q1 2025.